The DynamX Bioadaptor device was noninferior to DES for TLF overall, but a landmark analysis reveals a potential strength.

Purpose: The mechanism of action and pharmacokinetics of sirolimus when used as part of a drug ... To date, four major clinical trials have demonstrated the sirolimus-eluting stent to be safe ...

The trial was set up to give DCBs their “best shot” in this patient group, says one researcher, but it’s tough to beat current DES.

Novel drug-coated balloons (DCB) did not outshine standard treatment with second generation drug-eluting stents (DES ... the balloon is inflated, opening up the narrowed blood vessel and restoring ...

Undergoing percutaneous coronary intervention (PCI) for narrowed arteries with a novel bioadaptor is at least as effective as ...

The company's drug-eluting stent technologies have been developed through a technological collaboration with the prestigious ...

[34] Follow-up analysis demonstrated binary restenosis in 22% of BMS and 6% of PES patients (p = 0.021). By IVUS at 6 months, the percentage of neointimal volume obstruction was reduced with PES ...

Undergoing percutaneous coronary intervention (PCI) for narrowed arteries with a novel bioadaptor is at least as effective as a contemporary drug-eluting stent ... to date," said lead author ...

Drug-coated balloon (DCB) angioplasty as the initial strategy for de novo coronary artery stenoses didn't measure up to ...

or a Resolute Onyx zotarolimus-eluting stent (n = 1,198). Dual antiplatelet therapy was continued for at least 6 and 12 months in chronic and acute coronary syndromes, respectively. Total number of ...

Among patients undergoing non-cardiac surgery more than 1 year after coronary drug-eluting stent ... with longer follow-up. Using intravascular imaging to guide stent implantation during ...